There are several soluble predictive biomarkers of response to ICIs, such as PD-L1 expression, tumor mutation burden, specific tumor mutation (e.g. mutations in DNA replication or repair genes), and tumor-associated immune cell (e.g. CD8+ T cells) [3–5]. This evidence concerns the gene CD8A and neoplasm.